CA184-095_3: CA184-095, figure 3

CA184-095_3R Documentation

CA184-095, figure 3

Description

Kaplan-Meier digitized data from CA184-095, figure 3 (PMID 28034081). A reported sample size of 602 for a primary endpoint of OS in prostate cancer.

Usage

`CA184-095_3`

Format

A data frame of 602 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (ipilimumab, placebo)

Source

Beer TM, Kwon ED, Drake CG, et al. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. J Clin Oncol 2017; 35: 40–7.

Examples

summary(`CA184-095_3`)

kmplot(`CA184-095_3`)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.